Last reviewed · How we verify

Ritonavir boosted Atazanavir + 2 NRTIs

Fundacion SEIMC-GESIDA · FDA-approved active Small molecule

Ritonavir boosted Atazanavir + 2 NRTIs is a Protease inhibitor combination antiretroviral therapy Small molecule drug developed by Fundacion SEIMC-GESIDA. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.

Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV.

Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.

At a glance

Generic nameRitonavir boosted Atazanavir + 2 NRTIs
SponsorFundacion SEIMC-GESIDA
Drug classProtease inhibitor combination antiretroviral therapy
TargetHIV protease, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Atazanavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the maturation of infectious viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir concentrations and allowing for lower, more convenient dosing. The two nucleoside reverse transcriptase inhibitors (NRTIs) work synergistically by blocking reverse transcriptase, the enzyme HIV uses to convert its RNA genome into DNA.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ritonavir boosted Atazanavir + 2 NRTIs

What is Ritonavir boosted Atazanavir + 2 NRTIs?

Ritonavir boosted Atazanavir + 2 NRTIs is a Protease inhibitor combination antiretroviral therapy drug developed by Fundacion SEIMC-GESIDA, indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

How does Ritonavir boosted Atazanavir + 2 NRTIs work?

Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV.

What is Ritonavir boosted Atazanavir + 2 NRTIs used for?

Ritonavir boosted Atazanavir + 2 NRTIs is indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

Who makes Ritonavir boosted Atazanavir + 2 NRTIs?

Ritonavir boosted Atazanavir + 2 NRTIs is developed and marketed by Fundacion SEIMC-GESIDA (see full Fundacion SEIMC-GESIDA pipeline at /company/fundacion-seimc-gesida).

What drug class is Ritonavir boosted Atazanavir + 2 NRTIs in?

Ritonavir boosted Atazanavir + 2 NRTIs belongs to the Protease inhibitor combination antiretroviral therapy class. See all Protease inhibitor combination antiretroviral therapy drugs at /class/protease-inhibitor-combination-antiretroviral-therapy.

What development phase is Ritonavir boosted Atazanavir + 2 NRTIs in?

Ritonavir boosted Atazanavir + 2 NRTIs is FDA-approved (marketed).

What are the side effects of Ritonavir boosted Atazanavir + 2 NRTIs?

Common side effects of Ritonavir boosted Atazanavir + 2 NRTIs include Hyperbilirubinemia, Nausea, Diarrhea, Headache, Rash, Abdominal pain.

What does Ritonavir boosted Atazanavir + 2 NRTIs target?

Ritonavir boosted Atazanavir + 2 NRTIs targets HIV protease, HIV reverse transcriptase and is a Protease inhibitor combination antiretroviral therapy.

Related